Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Qiming Closes New China-Focused Fund with $1.1 Billion for Life Science and TMT Companies

publication date: Apr 9, 2020

Qiming closed its seventh China-focused US dollar fund with $1.1 billion for early stage Healthcare and TMT investments. Currently, Qiming manages nine US dollar funds and five RMB funds with $5.3 billion of assets under management. Despite the COVID-19 pandemic, Qiming said it closed Fund VII on time and at its target. Two years ago, Qiming announced its sixth dollar denominated fund with $935 million and, simultaneously, its fifth RMB fund with the equivalent of $334 million. Qiming has China offices in Shanghai, Beijing, Hong Kong and Shenzhen. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital